Lymphoma Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Lymphoma
| Protocol | SWOG S2114 |
|---|---|
| Cancer Type: | Lymphoma |
| Fast Facts |
A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1925 |
|---|---|
| Cancer Type: | CLL/SLL |
| Fast Facts |
RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG AHOD2131 |
|---|---|
| Cancer Type: | Classic Hodgkin Lymphoma |
| Fast Facts |
COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Patients must be 5 to 60 years of age at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | COG ANHL1931 |
|---|---|
| Cancer Type: | Lymphoma |
| Fast Facts |
COG ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
This is an AYA protocol ≥ 2 years
| Protocol | EAQ211 |
|---|---|
| Cancer Type: | Lymphoma |
| Fast Facts |
EAQ211: Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
